1,128 results on '"Tursi, Antonio"'
Search Results
2. Diverticular Inflammation and Complication Assessment (DICA) Classification
3. A model for the adsorption process of water dissolved elements flowing into reactive porous media: Characterization and sizing of water mining/filtering systems
4. Enhancing Oral 5-ASA Effectiveness in Mild-to-Moderate Ulcerative Colitis through an H. erinaceus -Based Nutraceutical Add-on Multi-Compound: The "HERICIUM-UC" Two-Arm Multicentre Retrospective Study.
5. Efficient reuse of Sargassum spp. biomass and organic fraction of municipal solid waste by anaerobic co-digestion in the Dominican Republic: Evaluation of biochemical methanogenic potential and reaction rates
6. Ustekinumab in the Treatment of Inflammatory Bowel Diseases: Evolving Paradigms
7. Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study
8. Segmental Colitis Associated with Diverticulosis
9. COVID-19 as a Trigger for De Novo Crohn’s Disease
10. Clinical use of biologics for Crohn’s disease in adults: lessons learned from real-world studies
11. Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study
12. Endoscopic appearance is not sufficient for a diagnosis of segmental colitis associated with diverticulosis
13. Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis
14. Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers
15. Contributors
16. Production of biodiesel from biomass
17. Biomass conversion
18. The prevalence of symptomatic uncomplicated diverticular disease could be lower than expected: a single-center colonoscopy-based cohort study
19. Performances of anti-TNFα antibodies as long-term maintenance therapy for ulcerative colitis
20. Successful treatment of concomitant Crohn’s disease and psoriasis with risankizumab
21. A comparison of different symptomatic reflux esophagitis treatments: A real-world study
22. Photocatalytic inactivation of Escherichia coli bacteria in water using low pressure plasma deposited TiO2 cellulose fabric
23. Publisher Correction: Colonic diverticular disease
24. Colonic diverticular disease
25. Author Correction: Colonic diverticular disease
26. MWCNTs Decorated with TiO2 as Highly Performing Filler in the Preparation of Nanocomposite Membranes for Scalable Photocatalytic Degradation of Bisphenol A in Water
27. How we can improve the appropriateness of ambulatory gastrointestinal endoscopy: the lesson of the COVID-19 outbreak
28. Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study
29. Risk factors for endoscopic severity of diverticular disease of the colon and its outcome: a real-life case-control study
30. Immune checkpoint inhibitors-induced acute diverticulitis
31. Anti-TNF-α Agents in Inflammatory Bowel Disease and Course of COVID-19
32. Pembrolizumab-induced acute diverticulitis
33. Public health and clinical utility of "dica" classification, " coda" score and fecal calprotectin in the management of patients with diverticular disease
34. Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study
35. Assessment of small intestinal bacterial overgrowth and methane production in patients on chronic proton-pump inhibitor treatment: prevalence and role of rifaximin in its management in primary care
36. Ulcerative Colitis After Complicated Diverticulitis
37. Assessment of small intestinal bacterial overgrowth and methane production in patients on chronic proton-pump inhibitor treatment: prevalence and role of rifaximin in its management in primary care
38. Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study
39. Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
40. Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study
41. Diverticular Inflammation and Complication Assessment classification, CODA score and fecal calprotectin in clinical assessment of patients with diverticular disease: A decision curve analysis
42. Prevalence and Natural History of Segmental Colitis Associated With Diverticulosis
43. Prevalence of celiac disease in family medicine setting: lower than expected and often with uncorrected diagnosis
44. Appropriateness of Proton Pump Inhibitor Prescription Evaluated by Using Serological Markers
45. Faecalibacterium prausnitzii is not decreased in symptomatic uncomplicated diverticular disease of the colon
46. Histological inflammation in ulcerative colitis in deep remission under treatment with infliximab
47. Evaluation of the Ecotoxicity of New Polyurethane Composites on Target Organisms for Aquatic and Atmospheric Environments
48. Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy
49. Faecalibacterium prausnitzii is not decreased in symptomatic uncomplicated diverticular disease of the colon
50. Editorial: Effectiveness and safety of ustekinumab in ulcerative colitis—Where we are now in real life.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.